Peptimmune
closedDrug company focused on the rare skin disease pemphigus vulgaris.
Cambridge Massachusetts (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$2.3m | Series A | ||
| N/A | $2.3m | Series A | |
$41.2m | Series B | ||
| N/A | $20.4m | Series C | |
$12.0m | Series C | ||
$8.2m | Series D | ||
$8.9m | Series D | ||
| Total Funding | CAD130m | ||
Related Content
Recent News about Peptimmune
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.